Transforming patient outcomes through manufacturing and commercialisation of groundbreaking cell and gene therapies. Cell and gene therapy science is highly complex. So too is the regulatory environment surrounding it. With deep experience in GMP-manufacturing of cell-based products, we offer an end-to-end portfolio of services to help develop and commercialise life-changing treatments with the potential to dramatically improve patient outcomes.
Cell Therapies Pty Ltd facility accredited by the Ministry of Health, Labour and Welfare in Japan. Cell Therapies Pty Ltd, a leading provider of cell and gene therapy products in the Asia Pacific region, is proud to announce that its proprietary facility has been accredited by.
Cell Therapies Pty Ltd facility accredited by the Ministry of Health, Labour and Welfare in Japan. Cell Therapies Pty Ltd, a leading provider of cell and gene therapy products in the Asia Pacific region, is proud to announce that its proprietary facility has been accredited by.
Services
Cell Therapies Pty Ltd (CTPL) is an Australian-based, globally-active commercial contract development and manufacturing company, specialising in cell therapy, gene therapy, regenerative medicine, and cellular immunotherapy products.
A leader in this groundbreaking field, our expert team and world-class facilities have been developing and manufacturing cutting edge treatments for cancer and rare diseases on behalf of local and international clients for more than 15 years.Apheresis collection protocol development, site selection and assessment, and network management.
A leader in this groundbreaking field, our expert team and world-class facilities have been developing and manufacturing cutting edge treatments for cancer and rare diseases on behalf of local and international clients for more than 15 years.Apheresis collection protocol development, site selection and assessment, and network management.
Established in 2003, Cell Therapies Pty Ltd (CTPL) is one of the most experienced cGMP compliant manufacturers for cell therapies, gene therapies, cellular immunotherapies and regenerative medicine products globally. Contract Development and Manufacturing (CDMO) of cell-based therapies to meet global regulatory requirements for clinical trials and commercial supply.
A/Prof Dominic Wall is the Chief Scientific Officer (CSO) for Cell Therapies Pty Ltd. As the CSO, he oversees the quality and production nominees for the purposes of licensing by the Therapeutic Goods Administration (TGA). At the Peter MacCallum Cancer Centre, Dominic has a joint appointment as the Executive Director for Business Ventures, leading its enterprises such as the external Pathology services.
Licensed GMP manufacturing and process development for clinical trials and commercial supply. Cell Therapies has been on the forefront of developing and executing clinical trial and commercial GMP manufacturing of cell-based products since 2003.
We have experience across a wide range of cell types, from mesenchymal stromal cells to chimaeric antigen receptor T-cells and offer full "needle-to-needle" process control - from patient cell collection back to reinfusion to the same patient.Process development and optimisation - ranging from process flexibility and rapid process scale-up for early stage clinical products, to cost reduction and standardisation for late-stage/commercial products.
We have experience across a wide range of cell types, from mesenchymal stromal cells to chimaeric antigen receptor T-cells and offer full "needle-to-needle" process control - from patient cell collection back to reinfusion to the same patient.Process development and optimisation - ranging from process flexibility and rapid process scale-up for early stage clinical products, to cost reduction and standardisation for late-stage/commercial products.
Control of apheresis collections can lead to improved manufacturability of cellular products. The management of clinical apheresis collections is critical to the success of many cell and gene therapy product candidates being developed today. Apheresis product is the most critical starting material in many of these manufacturing processes, with relatively few controls in place to ensure consistency and downstream manufacturability.
Reviews
Be the first to review Cell Therapies.
Write a Review
